» Articles » PMID: 33936173

Identification of a MicroRNA Signature Associated With Lymph Node Metastasis in Endometrial Endometrioid Cancer

Overview
Journal Front Genet
Date 2021 May 3
PMID 33936173
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Lymph node metastasis (LNM) is an important prognostic factor in endometrial cancer. Anomalous microRNAs (miRNAs) are associated with cell functions and are becoming a powerful tool to characterize malignant transformation and metastasis. The aim of this study was to construct a miRNA signature to predict LNM in endometrial endometrioid carcinoma (EEC).

Method: Candidate target miRNAs related to LNM in EEC were screened by three methods including differentially expressed miRNAs (DEmiRs), weighted gene co-expression network analysis (WGCNA), and decision tree algorithms. Samples were randomly divided into the training and validation cohorts. A miRNA signature was built using a logistic regression model and was evaluated by the area under the curve (AUC) of receiver operating characteristic curve (ROC) and decision curve analysis (DCA). We also conducted pathway enrichment analysis and miRNA-gene regulatory network to look for potential genes and pathways engaged in LNM progression. Survival analysis was performed, and the miRNAs were tested whether they expressed differently in another independent GEO database.

Result: Thirty-one candidate miRNAs were screened and a final 15-miRNA signature was constructed by logistic regression. The model showed good calibration in the training and validation cohorts, with AUC of 0.824 (95% CI, 0.739-0.912) and 0.821 (95% CI, 0.691-0.925), respectively. The DCA demonstrated the miRNA signature was clinically useful. Hub miRNAs in signature seemed to contribute to EEC progression mitotic cell cycle, cellular protein modification process, and molecular function. MiR-34c was statistically significant in survival that a higher expression of miR-34c indicated a higher survival time. MiR-34c-3p, miR-34c-5p, and miR-34b-5p were expressed differentially in GSE75968.

Conclusion: The miRNA signature could work as a noninvasive method to detect LNM in EEC with a high prediction accuracy. In addition, miR-34c cluster may be a key biomarker referring LNM in endometrial cancer.

Citing Articles

Lymph node metastasis determined miRNAs in esophageal squamous cell carcinoma.

Wei F, Bi S, Li M, Yu J Aging (Albany NY). 2024; 16(20):13104-13116.

PMID: 39401765 PMC: 11552642. DOI: 10.18632/aging.206122.


MiR-34b promotes oxidative stress and induces cellular senescence through TWIST1 in human cervical cancer.

Sindhu K, Nalini V, Suraishkumar G, Karunagaran D Transl Oncol. 2024; 48:102063.

PMID: 39094513 PMC: 11342277. DOI: 10.1016/j.tranon.2024.102063.


Predictive models for lymph node metastasis in endometrial cancer: A systematic review and bibliometric analysis.

Li H, Wang J, Zhang G, Li L, Shen Z, Zhai Z Womens Health (Lond). 2024; 20:17455057241248398.

PMID: 38725247 PMC: 11085025. DOI: 10.1177/17455057241248398.


The Role of miRNAs in the Development, Proliferation, and Progression of Endometrial Cancer.

Bogaczyk A, Zawlik I, Zuzak T, Kluz M, Potocka N, Kluz T Int J Mol Sci. 2023; 24(14).

PMID: 37511248 PMC: 10380838. DOI: 10.3390/ijms241411489.


Can miRNAs be useful biomarkers in improving prognostic stratification in endometrial cancer patients? An update review.

Ravegnini G, Gorini F, De Crescenzo E, De Leo A, de Biase D, Di Stanislao M Int J Cancer. 2021; 150(7):1077-1090.

PMID: 34706070 PMC: 9298718. DOI: 10.1002/ijc.33857.

References
1.
Chen X, Jin P, Tang H, Zhang L . miR-135a acts as a tumor suppressor by targeting ASPH in endometrial cancer. Int J Clin Exp Pathol. 2020; 12(9):3384-3389. PMC: 6949859. View

2.
Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E . Endometrial cancer. Lancet. 2015; 387(10023):1094-1108. DOI: 10.1016/S0140-6736(15)00130-0. View

3.
Li Y, Xie J, Xu X, Wang J, Ao F, Wan Y . MicroRNA-548 down-regulates host antiviral response via direct targeting of IFN-λ1. Protein Cell. 2012; 4(2):130-41. PMC: 4875363. DOI: 10.1007/s13238-012-2081-y. View

4.
Siegel R, Miller K, Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30. DOI: 10.3322/caac.21590. View

5.
Hiroki E, Suzuki F, Akahira J, Nagase S, Ito K, Sugawara J . MicroRNA-34b functions as a potential tumor suppressor in endometrial serous adenocarcinoma. Int J Cancer. 2011; 131(4):E395-404. DOI: 10.1002/ijc.27345. View